Technetium (99mTc) sulesomab

Source: Wikipedia, the free encyclopedia.
Technetium (99mTc) sulesomab
Fab' fragment
SourceMouse
TargetNCA-90 (granulocyte cell antigen)
Clinical data
ATC code
Legal status
Legal status
  • AU: Approved
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody[1] that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]

It is approved in European markets for the imaging of infections and inflammations in patients with suspected osteomyelitis[4][5] but has not secured FDA approval for use in American markets.[6] In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of soft tissue infections, malignant external otitis and prosthetic joint infection.[7][8][9] However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company Immunomedics was discontinued in 2018.[10]

References

  1. ^ "WHO Drug Information" (PDF). Archived from the original (PDF) on 2012-02-19. Retrieved 2009-10-25.
  2. PMID 18836272
    .
  3. from the original on 2019-12-10. Retrieved 2019-12-10.
  4. ^ EMEA: Summary of product characteristics (LeukoScan) Archived 2006-11-22 at the Wayback Machine
  5. PMID 25325395
    .
  6. .
  7. .
  8. .
  9. .
  10. ^ "Products". Immunomedics. Archived from the original on 2019-12-10. Retrieved 2019-12-10.

See also